According to the results of the cell-specific binding, cytotoxicity, and in vivo evaluation of the aptamer-drug conjugate ApDC, the HER2 aptamer conjugated to anticancer drug DM1 was able to specifically recognize the target cancer cells and therefore enhance the therapeutic efficacy of the drug. The gene discussed is ERBB2; the disease is cancer.